Andrés Pastor‐Fernández

Andrés Pastor‐Fernández

Auto-generated profile, based on publicly available information

Andrés Pastor‐Fernández

Metabolic Syndrome Group (BIOPROMET)

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMarcus J. G. W. Ladds
Marcus J. G. W. Ladds
ILIngeborg M. M. van Leeuwen
Ingeborg M. M. van Leeuwen
CDCatherine J. Drummond
Catherine J. Drummond
SCSu Chu
Su Chu
AHAlan Healy
Alan Healy
SLSonia Lain
Sonia Lain
The development of non-genotoxic therapies that activate wild-type p53 in tumors is of great interest since the discovery of p53 as a tumor suppressor. Here we report the identification of over 100 small-molecules activating p53 in cells. We elucidate the mechanism of action of a chiral tetrahydroindazole (HZ00), and through target deconvolution, we deduce that its active enantiomer (R)-HZ00, inhibits dihydroorotate dehydrogenase (DHODH). The chiral specificity of HZ05, a more potent analog, is revealed by the crystal structure of the (R)-HZ05/DHODH complex. Twelve other DHODH inhibitor chemotypes are detailed among the p53 activators, which identifies DHODH as a frequent target for structurally diverse compounds. We observe that HZ compounds accumulate cancer cells in S-phase, increase p53 synthesis, and synergize with an inhibitor of p53 degradation to reduce tumor growth in vivo. We, therefore, propose a strategy to promote cancer cell killing by p53 instead of its reversible cell cycle arresting effect.

26 January 2023 in Aging Cell
Verified
Journal Article
Open access
APAndrés Pastor‐Fernández
Andrés Pastor‐Fernández
ABAntonio R. Bertos
Antonio R. Bertos
ASArantzazu Sierra‐Ramírez
Arantzazu Sierra‐Ramírez
JMJavier del Moral‐Salmoral
Javier del Moral‐Salmoral
JMJavier Merino
Javier Merino
Cayetano Von KobbeCayetano Von Kobbe
Cayetano Von Kobbe
The enormous societal impact of the ongoing COVID‐19 pandemic has been particularly harsh for some social groups, such as the elderly. Recently, it has been suggested that senescent cells could play a central role in pathogenesis by exacerbating the pro‐inflammatory immune response against SARS‐CoV‐2. Therefore, the selective clearance of senescent cells by senolytic drugs may be useful as a therapy to ameliorate the symptoms of COVID‐19 in some cases. Using the established COVID‐19 murine model K18‐hACE2, we demonstrated that a combination of the senolytics dasatinib and quercetin (D/Q) significantly reduced SARS‐CoV‐2‐related mortality, delayed its onset, and reduced the number of other clinical symptoms. The increase in senescent markers that we detected in the lungs in response to SARS‐CoV‐2 may be related to the post‐COVID‐19 sequelae described to date. These results place senescent cells as central targets for the treatment of COVID‐19, and make D/Q a new and promising therapeutic tool.

21 March 2024 in Cancer Communications
Verified
Journal Article
Open access
APAndrés Pastor‐Fernández
Andrés Pastor‐Fernández
MHManuel Montero Gómez de las Heras
Manuel Montero Gómez de las Heras
JEJose Ignacio Escrig‐Larena
Jose Ignacio Escrig‐Larena
MBMarta Barradas
Marta Barradas
CPCristina Pantoja
Cristina Pantoja
DFDr. Pablo José Fernandez-Marcos
Dr. Pablo José Fernandez-Marcos

14 February 2023
Verified
Book Chapter
Closed access
PDF file
Magdalena Ramirez-PeñaMagdalena Ramirez-Peña
Magdalena Ramirez-Peña
MBMoises Batista
Moises Batista
Alberto Cerezo-NarváezAlberto Cerezo-Narváez
Alberto Cerezo-Narváez
Manuel Otero-MateoManuel Otero-Mateo
Manuel Otero-Mateo
APAndrés Pastor-Fernández
Andrés Pastor-Fernández

4 November 2022 in Cancer Communications
Verified
Journal Article
Open access
APAdrian Plaza
Adrian Plaza
APAndrés Pastor‐Fernández
Andrés Pastor‐Fernández
JLJosé L. López‐Aceituno
José L. López‐Aceituno
MBMarta Barradas
Marta Barradas
CPCristina Pantoja
Cristina Pantoja
DFDr. Pablo José Fernandez-Marcos
Dr. Pablo José Fernandez-Marcos